Status:
COMPLETED
Study With GW274150 In Patients With Mild Asthma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response. This will be c...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Mild asthma: taking reliever medication (e.g. salbutamol) only.
- Screening involves measuring responses to the lung challenge agents: allergen, AMP, and methacholine. Only those with specific types of response to these will be eligible for the study.
- Exclusion criteria:
- Recent steroid treatment.
- Significant illnesses or diseases other than asthma.
Exclusion
Key Trial Info
Start Date :
November 15 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 28 2005
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00273013
Start Date
November 15 2004
End Date
October 28 2005
Last Update
October 18 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Manchester, Lancashire, United Kingdom, M23 9LT
2
GSK Investigational Site
London, United Kingdom, SE1 9RT